Supplemental Disclosure for Statement of Cash Flows	9 Months Ended
Apr. 30, 2025
Supplemental Disclosure for Statement of Cash Flows [Abstract]
Supplemental disclosure for statement of cash flows	Note 5 – Supplemental disclosure for statement of cash flows During the nine months ended April 30, 2025 and 2024, interest paid by the Company was $3 and $275, respectively. For the nine months ended April 30, 2025 and 2024, the net reductions in the measurement of right-of-use assets and operating lease liabilities, including those of discontinued operations, was $1,187 and $306, respectively and are included in cash flows used in operating activities. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statements of cash flows. The Company added new right-of-use assets and operating lease liabilities of $106 and $0 for the nine months ended April 30, 2025 and 2024, respectively. In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs at the end of fiscal 2023, $5,000 of escrowed proceeds are included in cash in escrow as of July 31, 2024. As of April 30, 2025, these escrowed proceeds were released to the Company. In connection with the full payment of a mortgage in July 2023, the restricted cash collateral deposit of $1,000 was released during the nine months ended April 30, 2024. During the nine months ended April 30, 2025, the Company disbursed $163 for taxes related to net share settlement of a bonus paid in stock to a senior executive. During the nine months ended April 30, 2024, the Company disbursed $467 for taxes related to net share settlement of bonuses paid in stock to a senior executive and a former senior executive. For the nine months ended April 30, 2025 and 2024, tax on capital paid by the Company was $8 and $23, respectively. During the nine months ended April 30, 2024, state taxes paid on the gain on the completed sale of certain assets used in the operation of Enzo Clinical Labs were $729. On October 29, 2024, the Board of Directors of the Company declared a special cash dividend of $0.10 per share on its common stock, which was paid on December 2, 2024, to the holders of record entitled to dividends as of the close of business on November 15, 2024. The total dividend paid was $5,324.

Supplemental Disclosure for Statement of Cash Flows

9 Months Ended

Apr. 30, 2025

Supplemental Disclosure for Statement of Cash Flows [Abstract]

Supplemental disclosure for statement of cash flows

Note 5 – Supplemental disclosure for statement of cash flows

During the nine months ended April 30, 2025 and 2024, interest paid by the Company was $3 and $275, respectively.

For the nine months ended April 30, 2025 and 2024, the net reductions in the measurement of right-of-use assets and operating lease liabilities, including those of discontinued operations, was $1,187 and $306, respectively and are included in cash flows used in operating activities. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statements of cash flows.

The Company added new right-of-use assets and operating lease liabilities of $106 and $0 for the nine months ended April 30, 2025 and 2024, respectively.

In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs at the end of fiscal 2023, $5,000 of escrowed proceeds are included in cash in escrow as of July 31, 2024. As of April 30, 2025, these escrowed proceeds were released to the Company. In connection with the full payment of a mortgage in July 2023, the restricted cash collateral deposit of $1,000 was released during the nine months ended April 30, 2024.

During the nine months ended April 30, 2025, the Company disbursed $163 for taxes related to net share settlement of a bonus paid in stock to a senior executive. During the nine months ended April 30, 2024, the Company disbursed $467 for taxes related to net share settlement of bonuses paid in stock to a senior executive and a former senior executive.

For the nine months ended April 30, 2025 and 2024, tax on capital paid by the Company was $8 and $23, respectively. During the nine months ended April 30, 2024, state taxes paid on the gain on the completed sale of certain assets used in the operation of Enzo Clinical Labs were $729.

On October 29, 2024, the Board of Directors of the Company declared a special cash dividend of $0.10 per share on its common stock, which was paid on December 2, 2024, to the holders of record entitled to dividends as of the close of business on November 15, 2024. The total dividend paid was $5,324.